The clinical incidence of neutralising factors developing in cancer patients treated systemically is 2.9% and in chronic hepatitis patients is 6.2%.
Hoolimata madalast neutraliseerivate faktorite tiitrist ei täheldatud hepatiidiga patsientidel reaktsiooni vim